FDA Submits Final Proposals for PDUFA IV
ePT--the Electronic Newsletter of Pharmaceutical Technology
Rockville, MD (Mar. 23)-The US Food and Drug Administration has submitted to Congress its final proposals for reauthorizing the fourth Prescription Drug User Fee Act (PDUFA IV), which will follow the expiration of the current user-fee on September 30, 2007.
Rockville, MD (Mar. 23)-The US Food and Drug Administration (FDA, www.fda.gov) submitted to Congress its final proposals for reauthorizing the fourth Prescription Drug User Fee Act (PDUFA IV), which will follow the expiration of the current user fee on September 30, 2007. The law provides user-fee funds paid by brand drug and biotechnology companies that help support the review of new drugs.
According to an FDA release, annual user fees under PDUFA IV would increase to $392.8 million, an $87.4 million increase over PDUFA III.
The funds would support “key goals,” including enhancing premarket review and creating a modern postmarket drug safety system that follows products across their full life cycle.
“Our proposed recommendations for PDUFA IV aim to strengthen our drug safety system and upgrade resources to enhance FDA’s information technology capability,” said Commissioner of Food and Drugs Andrew C. von Eschenbach, MD.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
